Key Takeaways Trinity Biotech's CGM+ trial confirmed accurate 15-day glucose tracking without finger-stick calibration.TRIB's redesigned sensor cuts disposable components, lowering cost compared to current CGM products.TRIB's AI-native CGM+ aims to integrate health metrics and target the $260 billion AI wearables market.Trinity Biotech plc (TRIB) announced compelling positive clinical trial results with respect to its next-generation continuous glucose monitoring (CGM) technology, CGM+, on Tuesday. The tria ...